The modular nature of our proprietary ACTR and BOXR technology platforms enables a variety of opportunities to collaborate with potential partners.
Our goal is to leverage our platform technologies and access complimentary capabilities to accelerate development and commercialization of our existing product pipeline and create highly differentiated cell therapy product candidates.
To learn more about partnership opportunities with Unum Therapeutics, please contact us: email@example.com.
In June 2015, we entered into a strategic collaboration with Seattle Genetics (SGEN) to co-develop and co-promote Unum Therapeutics' universal ACTR receptor in combination with select SGEN antibodies. The first product candidate from this collaboration is ACTR087 used in combination with SEA-BCMA, which we are currently testing in a Phase I clinical trial in r/r multiple myeloma. Read more about the collaboration here.